Cara Therapeutics Company Profile (NASDAQ:CARA)

About Cara Therapeutics (NASDAQ:CARA)

Cara Therapeutics logoCara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body's peripheral nervous system. The Company operates through the activities related to the discovery and development of therapeutics to treat serious medical conditions, including pain and pruritus. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845 for acute and chronic pain, and CR701 for neuropathic and inflammatory pain. I.V. CR845 is an injectable version of peripheral kappa opioid receptor agonist, which is intended for the treatment of acute pain in an acute care setting. CR845 has exhibited anti-pruritic, or anti-itch, potency in standard preclinical models.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CARA
  • CUSIP: N/A
  • Web:
  • Market Cap: $547.09 million
  • Outstanding Shares: 32,507,000
Average Prices:
  • 50 Day Moving Avg: $16.69
  • 200 Day Moving Avg: $13.63
  • 52 Week Range: $4.35 - $20.90
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.48
  • P/E Growth: 0.000
Sales & Book Value:
  • Annual Revenue: $990,000.00
  • Price / Sales: 552.62
  • Book Value: $0.90 per share
  • Price / Book: 18.70
  • EBIDTA: ($68,880,000.00)
  • Return on Equity: -50.62%
  • Return on Assets: -46.58%
  • Current Ratio: 11.29%
  • Quick Ratio: 11.29%
  • Average Volume: 2.10 million shs.
  • Beta: 3.29
  • Short Ratio: 33.42

Frequently Asked Questions for Cara Therapeutics (NASDAQ:CARA)

What is Cara Therapeutics' stock symbol?

Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA."

How were Cara Therapeutics' earnings last quarter?

Cara Therapeutics Inc (NASDAQ:CARA) issued its quarterly earnings results on Thursday, May, 4th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.73) by $0.08. The firm had revenue of $0.91 million for the quarter, compared to analyst estimates of $0.11 million. The business's quarterly revenue was up 12900.0% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.39) earnings per share. View Cara Therapeutics' Earnings History.

When will Cara Therapeutics make its next earnings announcement?

Cara Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for Cara Therapeutics.

Where is Cara Therapeutics' stock going? Where will Cara Therapeutics' stock price be in 2017?

11 brokerages have issued 1 year price objectives for Cara Therapeutics' shares. Their predictions range from $22.00 to $35.00. On average, they anticipate Cara Therapeutics' stock price to reach $28.08 in the next twelve months. View Analyst Ratings for Cara Therapeutics.

What are analysts saying about Cara Therapeutics stock?

Here are some recent quotes from research analysts about Cara Therapeutics stock:

  • 1. According to Zacks Investment Research, "Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States. " (5/10/2017)
  • 2. HC Wainwright analysts commented, "CR845 as safe as placebo in respiratory safety Phase 1. Cara announced positive data this morning from a 15-patient Phase 1 trial in healthy volunteers designed to formally test for IV ‘845’s impact on respiratory drive, as respiratory depression remains one of the more severe, and potentially life-threatening, side effects of mu opioids, which ‘845 is not. The trial was a three-way crossover design utilizing the expected therapeutic dose of 1.0 ug/kg, as well as a 5.0 ug/kg supratherapeutic dose to test the upper bounds for safety. Patient respiratory drive was measured via end-tidal CO2 (ETCO2), oxygen saturation (SpO2), and respiratory rate, with primary endpoints focused on the former two. ETCO2 ranged from 36.1 to 37.8 mmHg prior to dosing, and remained well below the endpoint threshold of a 10mmHg sustained increase in ETCO2, with values of 38.1, 38.1, and 38.3 mmHg for the placebo, 1.0 ug/kg, and 5.0 ug/kg doses, respectively, one hour after administration. Both doses of ‘845 also hit on the SpO2 primary endpoint (needed to show SpO2 which did not consistently fall below 92%), with pre-treatment levels ranging from 98.3% to 98.9%, finishing an hour later at 97.8%, 98.2%, and 97.9% for the placebo,1.0 ug/kg, and 5.0 ug/kg doses, respectively. While these two primary endpoints only measured through an hour after treatment, no significant differences were seen on all three measures of respiratory drive throughout the entire 4-hour observation period of the study." (4/24/2017)
  • 3. Cantor Fitzgerald analysts commented, "The Phase 1 safety trial of IV CR845 showed no significant differences in respiratory drive vs. placebo at super-therapeutic dosing levels." (4/24/2017)
  • 4. Piper Jaffray Companies analysts commented, "Today Cara reported positive results from Part A of its Phase II/III trial for IV CR845 in uremic pruritus (UP). In our view, these results are compelling in terms of impact on worst itching scores together with more global measures of quality of life within the context of an 8-week study, as well as safety/tolerability at the go-forward doses of 0.5mcg/kg and 1.0mcg/kg. We see the robust efficacy vs safety data from this Phase II as reducing clinical risk for a broader pivotal program planned to begin by YE17. And beyond the Phase III program, we see this dataset as potentially reducing regulatory and commercial risk, and enhancing value of this asset, in the longer-term. In advance of further clinical progress in UP, including an EOP2 and Phase III start yet in '17, as well as chronic pain and post-op pain updates during 2Q17, we reiterate OW on Cara." (3/28/2017)
  • 5. Needham & Company LLC analysts commented, "Cara announced positive results from Phase 2/3 trial of IV CR845 in Uremic Pruritus (Itch associated w/ Hemodialysis pts). Part A of trial met both primary endpt in itch reduction and secondary endpt in Skindex-10 quality of life. Effect size increased relative to placebo over time and we believe findings are clinically meaningful. Safety/ tolerability of lower two doses appears acceptable. End of Phase 2 mtg planned and mgmt guided for initiation 12wk Phase 3 trial (Part B) by YE17. A 2nd Phase 3 trial may be needed, subject to FDA. Cara also plans to initiate open-label 12mo Phase 3 trial in 3Q17." (3/28/2017)

Are investors shorting Cara Therapeutics?

Cara Therapeutics saw a increase in short interest in the month of April. As of April 13th, there was short interest totalling 5,942,697 shares, an increase of 19.8% from the March 31st total of 4,962,108 shares. Based on an average daily volume of 2,606,962 shares, the short-interest ratio is presently 2.3 days.

Who are some of Cara Therapeutics' key competitors?

Who owns Cara Therapeutics stock?

Cara Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include RHO Capital Partners Inc. (13.07%), Vanguard Group Inc. (3.46%), FMR LLC (3.44%), Chescapmanager LLC (3.27%), JPMorgan Chase & Co. (1.27%) and Morgan Stanley (1.22%). Company insiders that own Cara Therapeutics stock include Derek T Chalmers, Frederique PhD Menzaghi, Josef Schoell, Michael E Lewis and Ventures Vi Lp Rho. View Institutional Ownership Trends for Cara Therapeutics.

Who sold Cara Therapeutics stock? Who is selling Cara Therapeutics stock?

Cara Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including C WorldWide Group Holding A S, Janney Montgomery Scott LLC, Ameriprise Financial Inc., Dimensional Fund Advisors LP, JPMorgan Chase & Co., Goldman Sachs Group Inc., Baldwin Brothers Inc. MA and EAM Investors LLC. View Insider Buying and Selling for Cara Therapeutics.

Who bought Cara Therapeutics stock? Who is buying Cara Therapeutics stock?

Cara Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, RHO Capital Partners Inc., Jennison Associates LLC, UBS Asset Management Americas Inc., Morgan Stanley, Chescapmanager LLC, Vanguard Group Inc. and Monashee Investment Management LLC. Company insiders that have bought Cara Therapeutics stock in the last two years include Josef Schoell and Ventures Vi Lp Rho. View Insider Buying and Selling for Cara Therapeutics.

How do I buy Cara Therapeutics stock?

Shares of Cara Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Cara Therapeutics stock cost?

One share of Cara Therapeutics stock can currently be purchased for approximately $16.83.

Analyst Ratings

Consensus Ratings for Cara Therapeutics (NASDAQ:CARA) (?)
Ratings Breakdown: 1 Hold Rating, 10 Buy Ratings
Consensus Rating:Buy (Score: 2.91)
Consensus Price Target: $28.08 (66.86% upside)

Analysts' Ratings History for Cara Therapeutics (NASDAQ:CARA)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/19/2017Cantor FitzgeraldReiterated RatingOverweight$29.00LowView Rating Details
5/17/2017Canaccord GenuityReiterated RatingBuy$25.00HighView Rating Details
5/15/2017ScotiabankBoost Price TargetOutperform$33.00 -> $34.00N/AView Rating Details
5/15/2017Royal Bank of CanadaLower Price TargetOutperform$32.00 -> $31.00N/AView Rating Details
5/15/2017Raymond James Financial, Inc.Lower Price TargetMarket Perform$30.00 -> $28.00N/AView Rating Details
5/15/2017CIBCBoost Price Target$28.00 -> $29.00N/AView Rating Details
4/24/2017HC WainwrightReiterated RatingBuy$30.00MediumView Rating Details
4/6/2017Piper Jaffray CompaniesReiterated RatingBuy$27.00LowView Rating Details
3/29/2017Janney Montgomery ScottBoost Price TargetBuy$20.00 -> $22.00LowView Rating Details
3/28/2017Needham & Company LLCReiterated RatingBuy -> Positive$23.00HighView Rating Details
3/28/2017LaidlawReiterated RatingBuy -> Buy$20.00 -> $35.00HighView Rating Details
8/5/2016Stifel NicolausLower Price TargetBuy$25.00 -> $24.00N/AView Rating Details
(Data available from 5/22/2015 forward)


Earnings History for Cara Therapeutics (NASDAQ:CARA)
Earnings by Quarter for Cara Therapeutics (NASDAQ:CARA)
Earnings History by Quarter for Cara Therapeutics (NASDAQ:CARA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017($0.73)($0.81)$0.11 million$0.91 millionViewListenView Earnings Details
11/3/2016Q3($0.47)($0.42)$0.09 millionViewN/AView Earnings Details
8/4/2016Q216($0.42)($0.48)$0.13 million$0.08 millionViewN/AView Earnings Details
5/5/2016Q116($0.40)($0.39)$0.03 million$0.01 millionViewN/AView Earnings Details
3/10/2016Q4($0.33)($0.35)$0.53 millionViewListenView Earnings Details
11/9/2015Q315($0.27)($0.19)$1.86 million$2.40 millionViewN/AView Earnings Details
8/10/2015Q215($0.24)($0.25)$0.50 million$0.87 millionViewListenView Earnings Details
5/12/2015Q415($0.22)($0.21)$0.70 million$0.50 millionViewListenView Earnings Details
3/26/2015Q4($0.28)($0.18)$1.00 million$0.91 millionViewListenView Earnings Details
11/10/2014Q314($0.22)($0.29)$0.13 million$1.13 millionViewN/AView Earnings Details
8/7/2014Q2($0.27)($0.16)$0.08 million$0.96 millionViewN/AView Earnings Details
5/12/2014Q1($0.14)($0.22)$0.30 million$0.18 millionViewN/AView Earnings Details
3/27/2014($0.18)($0.49)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Cara Therapeutics (NASDAQ:CARA)
Current Year EPS Consensus Estimate: $-2.35 EPS
Next Year EPS Consensus Estimate: $-2.25 EPS


Dividend History for Cara Therapeutics (NASDAQ:CARA)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Cara Therapeutics (NASDAQ:CARA)
Insider Ownership Percentage: 7.70%
Institutional Ownership Percentage: 43.29%
Insider Trades by Quarter for Cara Therapeutics (NASDAQ:CARA)
Institutional Ownership by Quarter for Cara Therapeutics (NASDAQ:CARA)
Insider Trades by Quarter for Cara Therapeutics (NASDAQ:CARA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/31/2017Ventures Vi Lp RhoMajor ShareholderBuy500,000$18.19$9,095,000.00View SEC Filing  
4/20/2016Frederique Ph.D. MenzaghiVPSell6,000$9.00$54,000.00View SEC Filing  
3/17/2016Ventures Vi Lp RhoMajor ShareholderBuy400,000$4.87$1,948,000.00View SEC Filing  
2/3/2016Frederique Ph.D. MenzaghiVPSell6,000$9.04$54,240.00View SEC Filing  
1/26/2016Michael E LewisInsiderSell7,262$10.93$79,373.66View SEC Filing  
1/6/2016Derek T ChalmersCEOSell12,500$17.22$215,250.00View SEC Filing  
12/1/2015Frederique Ph.D. MenzaghiVPSell6,000$16.21$97,260.00View SEC Filing  
11/2/2015Frederique Ph.D. MenzaghiVPSell6,000$14.26$85,560.00View SEC Filing  
10/1/2015Frederique Ph.D. MenzaghiVPSell6,000$13.95$83,700.00View SEC Filing  
9/1/2015Frederique Ph.D. MenzaghiVPSell7,000$18.63$130,410.00View SEC Filing  
8/18/2015Josef SchoellCFOBuy3,000$22.10$66,300.00View SEC Filing  
6/1/2015Michael E LewisInsiderSell7,262$9.50$68,989.00View SEC Filing  
5/19/2015Dean SlagelDirectorSell188,811$10.02$1,891,886.22View SEC Filing  
4/1/2015Michael E LewisInsiderSell7,262$9.90$71,893.80View SEC Filing  
3/2/2015Michael E LewisInsiderSell7,262$10.11$73,418.82View SEC Filing  
2/2/2015Michael E LewisInsiderSell7,262$10.60$76,977.20View SEC Filing  
2/5/2014Ventures Vi Lp RhoMajor ShareholderBuy225,818$11.00$2,483,998.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Cara Therapeutics (NASDAQ:CARA)
Latest Headlines for Cara Therapeutics (NASDAQ:CARA)
DateHeadline logoCara Therapeutics Inc (CARA) Receives "Overweight" Rating from Cantor Fitzgerald - May 20 at 9:00 AM logoCara Therapeutics to Present at the 17th Annual Conference on Pain Therapeutics - GlobeNewswire (press release) - May 19 at 9:05 PM logoThe Best- and Worst-Performing Marijuana Stocks Last Week - May 18 at 11:25 AM logoCara Therapeutics Inc (CARA) Given "Buy" Rating at Canaccord Genuity - May 17 at 9:08 PM logoCara Therapeutics to Present at the 17th Annual Conference on Pain Therapeutics - May 17 at 11:48 AM logoCara Therapeutics: A Look At The Next Catalyst - Osteoarthritis - Seeking Alpha - May 16 at 4:11 PM logoCara Therapeutics: A Tool To Fight The Opioid Epidemic? - May 16 at 11:18 AM logoCARA Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CARA-US : May 15, 2017 - May 15 at 11:28 AM logoWhy You're Smart to Buy Cara Therapeutics Stock - Motley Fool - May 14 at 4:15 PM logoCara Therapeutics to Host KOL Meeting on Chronic Kidney Disease-Associated Pruritus on May 16, 2017 - GlobeNewswire (press release) - May 12 at 4:42 PM logoWhy You're Smart to Buy Cara Therapeutics Stock - May 12 at 4:42 PM logoCara Therapeutics to Host KOL Meeting on Chronic Kidney Disease-Associated Pruritus on May 16, 2017 - May 12 at 4:42 PM logoFY2017 Earnings Estimate for Cara Therapeutics Inc Issued By Cantor Fitzgerald (CARA) - May 12 at 1:18 PM logoCara Therapeutics Inc (CARA) Stock Rating Reaffirmed by Cantor Fitzgerald - May 12 at 10:30 AM logoETFs with exposure to CARA Therapeutics, Inc. : May 11, 2017 - May 11 at 4:45 PM logoZacks Investment Research Upgrades Cara Therapeutics Inc (CARA) to Hold - May 10 at 5:22 PM logoCARA Therapeutics, Inc. :CARA-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017 - May 9 at 4:09 PM logoWhy Did Cara Therapeutics Shares Tumble 13.6% in April? - May 6 at 4:29 PM logoCara Therapeutics Inc (CARA) Releases Earnings Results, Misses Expectations By $0.08 EPS - May 5 at 5:44 PM logoBRIEF-Cara Therapeutics Q1 loss per share $0.81 - May 4 at 9:19 PM logoCara reports 1Q loss - May 4 at 4:24 PM logoCara Therapeutics Reports First Quarter 2017 Financial Results - Nasdaq - May 4 at 4:17 PM logoInvestor Network: Cara Therapeutics Inc to Host Earnings Call - May 4 at 4:17 PM logoCara Therapeutics Reports First Quarter 2017 Financial Results - May 4 at 4:17 PM logoCara Therapeutics (CARA) Getting Favorable Press Coverage, Study Finds - May 4 at 2:48 PM logoCara Therapeutics Inc (CARA) Receives Average Recommendation of "Buy" from Analysts - May 2 at 12:38 PM logoCara Therapeutics (CARA) Getting Somewhat Favorable Press Coverage, Analysis Shows - May 1 at 2:44 PM logoShort Interest in Cara Therapeutics Inc (CARA) Expands By 19.8% - April 30 at 4:18 PM logoCara Therapeutics to Announce First Quarter 2017 Financial Results on May 4, 2017 - GlobeNewswire (press release) - April 29 at 4:45 PM logoCara Therapeutics Inc (CARA) Given "Market Perform" Rating at Raymond James Financial, Inc. - April 28 at 11:24 PM logoSomewhat Favorable Press Coverage Somewhat Likely to Affect Cara Therapeutics (CARA) Share Price - April 27 at 8:12 PM logoCara Therapeutics Announces Positive Data From Quantitative Phase 1 Trial Measuring Respiratory Safety of I.V. CR845 - Yahoo Finance - April 26 at 2:59 PM logoCramer's lightning round: Nobody ever made money betting against this CEO - April 25 at 12:22 PM logoSomewhat Favorable News Coverage Somewhat Likely to Affect Cara Therapeutics (CARA) Share Price - April 24 at 8:08 PM logoCara Therapeutics Inc (CARA) Receives "Buy" Rating from HC Wainwright - April 24 at 6:40 PM logoGlobal Medical Marijuana Market 2014-2017 & 2025 - Analysis of Chronic Pain, Arthritis, Migraine & Cancer Markets - Research and Markets - April 24 at 4:05 PM logoCara Therapeutics (CARA) Reports Positive Quantitative Phase 1 Trial Data Measuring Respiratory Safety of I.V. CR845 - April 24 at 4:05 PM logoCantor Fitzgerald Reaffirms Buy Rating for Cara Therapeutics Inc (CARA) - April 24 at 12:22 PM logoBRIEF-Cara Therapeutics announces positive data - April 24 at 9:49 AM logoCara Therapeutics (CARA) Getting Somewhat Favorable Media Coverage, Study Finds - April 21 at 2:02 PM logoToday's Research Reports on Biotech Stocks to Watch: Cara Therapeutics and Incyte - Yahoo Finance - April 19 at 6:14 PM logoIs Cara Therapeutics About to Change How We Treat Pain? - Motley Fool - April 19 at 6:14 PM logoFavorable News Coverage Somewhat Likely to Affect Cara Therapeutics (CARA) Stock Price - April 18 at 1:37 PM logoTraders Buy Large Volume of Call Options on Cara Therapeutics (CARA) - April 17 at 2:02 PM logoCara Therapeutics (CARA) Earning Somewhat Favorable Media Coverage, Analysis Shows - April 14 at 7:57 PM logoCara Therapeutics Inc (CARA) Upgraded to "Strong-Buy" by Vetr Inc. - April 14 at 9:30 AM logoBiotech Stocks on Investors' Radar -- Halozyme Therapeutics, Cara Therapeutics, PDL BioPharma, and Arena Pharma - April 13 at 4:15 PM logoBiotech Stocks on Investors' Radar -- Halozyme Therapeutics, Cara Therapeutics, PDL BioPharma, and - PR Newswire (press release) - April 13 at 6:53 AM logoWhy Cara Theraputics Will Soar - Seeking Alpha - April 9 at 11:57 AM logoCara Therapeutics Inc (CARA) Upgraded by Vetr Inc. to Buy - April 8 at 5:33 PM


Cara Therapeutics (CARA) Chart for Monday, May, 22, 2017

This page was last updated on 5/22/2017 by Staff